Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) https://validator.w3.org/feed/docs/rss2.html Our Team Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) AP-SciBio 2027 x WIC APAC 2027 & Thai Immunology Annual Meeting CAR T-cell Immunometabolism: Insights from Patients TTCI to Participate in WIC-APAC 2026 Personalized Cancer Vaccines – A New Frontier in Thailand’s Fight Against Cancer Member Contents Thailand Successfully Hosts Its First WIC APAC Webinar, Drawing Strong Regional Interest in Personalized Cancer Vaccines TTCI Representative Highlights CAR-T Cell Therapy Roadmap at the 74th JSTMCT Annual Meeting in Yokohama TTCI Researchers Present and Collaborate at the 29th Annual Meeting of the Japanese Association of Cancer Immunology CAR T-cell therapy for paediatric solid tumours: clinical trial development and preclinical modelling Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy Basic Cancer Immunology for Clinicians A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML TTCI at a glance Chiang Mai University Team Mahidol University Team NRCT Hosts Seminar on “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment” at MHESI Fair 2025 Thai Immunology Annual Meeting 2026 Antibody-Drug Conjugates (ADCs): Recent Advances in the Treatment of Solid Tumors International Collaborator IPOPI | SEAPID | Chulalongkorn | Erasmus MC Meeting 2026 Pediatric Neuro-Oncology Consortium – Chulalongkorn University Research Forum Cell Therapy for Solid Cancers: Promise or Overpromise? Scientific Meeting: Medical Applications of Gene Editing and Synthetic Biology Technologies White Paper TTCI Webinar “CAR T-cell Immunometabolism, Insights from Patients” Government Agencies and Related Announcements Efficiently targeting folate receptor alpha-positive ovarian cancer by human antibody VH domain-based chimeric antigen receptor (CAR) IMMUNOLOGY SEMINAR: PEPTIDE CANCER VACCINE EXPERIENCE AT NCI Enhancing T cell cytotoxicity against lung cancer with an αPD-L1 protein engager and gemcitabine combination therapy Registration Open: 1st International Scientific Symposium in Hematologic Malignancy (CETH, Chulalongkorn University) Khonkaen University Team Thammasat University Team Chulalongkorn University Team Equipment University of Wisconsin School of Medicine and Public Health Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody TTCI Members Receive Research Recognition Awards from Faculty of Sciences, Chiang Mai University Celebrating Excellence in Immunotherapy: Dr. Piriya Luangwattananun Honored as Young Investigator Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy New Immune Cell Engager Combined with Chemotherapy Boosts Attack on Multiple Myeloma A multi-center clinical research project to study the Safety and Efficacy of CD19 CAR T-cells in ALL (Acute Lymphoblastic Leukemia) by Academic Hubs Researchers Develop Method to Remove Specific Problematic Proteins for Improved Drug Effects Enhancing Innate and Adaptive Immunity to Combat Multiple Myeloma: Combined Use of Trispecific NK Cell Engagers (TriKEs) and Bispecific T-Cell Engagers (BiTEs) in Immunotherapy Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody New Dual-Targeting Protein and Chemotherapy Boost T-Cell Attack on Lung Cancer Vaccine and Therapeutic RNA Research Forum 2025 Patient Care and Toxicities Management of CAR T-cell in Pediatrics